WIDE MOAT STOCKS COMPARISON

Checking

 

Stock Comparison

Amgen Inc. vs Johnson & Johnson

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Amgen Inc.

AMGN · Nasdaq Stock Market

Market cap (USD)$236B
Gross margin (TTM)72.7%
Operating margin (TTM)33.2%
Net margin (TTM)22.9%
SectorHealthcare
IndustryPharmaceuticals
CountryUS
Data as of2026-08-23
62/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Amgen Inc.'s moat claims, evidence, and risks.

View AMGN analysis

Johnson & Johnson

JNJ · New York Stock Exchange

Market cap (USD)$663.3B
Gross margin (TTM)70.5%
Operating margin (TTM)26.8%
Net margin (TTM)21.5%
SectorHealthcare
IndustryPharmaceuticals
CountryUS
Data as of2026-08-23
73/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Johnson & Johnson's moat claims, evidence, and risks.

View JNJ analysis

Comparison highlights

  • Moat score gap: Johnson & Johnson leads (73 / 100 vs 62 / 100 for Amgen Inc.).
  • Segment focus: Amgen Inc. has 3 segments (75.5% in Core Innovative Medicines); Johnson & Johnson has 2 segments (64.7% in Innovative Medicine).
  • Moat breadth: Amgen Inc. has 2 moat types across 2 domains; Johnson & Johnson has 3 across 2.

Primary market context

Amgen Inc.

Core Innovative Medicines

Market

Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)

Geography

Global

Customer

Payers, providers, and pharmacies

Role

Drug developer/manufacturer

Revenue share

75.5%

Johnson & Johnson

Innovative Medicine

Market

Branded prescription pharmaceuticals (biopharma)

Geography

Global

Customer

Wholesalers, hospitals, retailers, healthcare professionals, payers

Role

Drug discovery, development, manufacturing, commercialization

Revenue share

64.7%

Side-by-side metrics

Amgen Inc.
Johnson & Johnson
Ticker / Exchange
AMGN - Nasdaq Stock Market
JNJ - New York Stock Exchange
Market cap (USD)
$236B
$663.3B
Gross margin (TTM)
72.7%
70.5%
Operating margin (TTM)
33.2%
26.8%
Net margin (TTM)
22.9%
21.5%
Sector
Healthcare
Healthcare
Industry
Pharmaceuticals
Pharmaceuticals
HQ country
US
US
Primary segment
Core Innovative Medicines
Innovative Medicine
Market structure
Competitive
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
62 / 100
73 / 100
Moat domains
Legal, Supply
Legal, Demand
Last update
2026-09-05
2026-09-05

Moat coverage

Shared moat types

IP Choke Point

Amgen Inc. strengths

Capex Knowhow Scale

Johnson & Johnson strengths

Training Org Change CostsBrand Trust

Segment mix

Amgen Inc. segments

Full profile >

Core Innovative Medicines

Competitive

75.5%

Rare Disease Portfolio (Horizon + others)

Competitive

16%

Biosimilars

Competitive

8.5%

Johnson & Johnson segments

Full profile >

Innovative Medicine

Competitive

64.7%

MedTech

Oligopoly

35.3%

Act on this comparison

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.